33 related articles for article (PubMed ID: 4889009)
1. Aspartate transcarbamylase. Studies of the catalytic subunit by ultraviolet difference spectroscopy.
Collins KD; Stark GR
J Biol Chem; 1969 Apr; 244(7):1869-77. PubMed ID: 4889009
[No Abstract] [Full Text] [Related]
2. Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease.
Del Caño-Ochoa F; Ramón-Maiques S
Protein Sci; 2021 Oct; 30(10):1995-2008. PubMed ID: 34288185
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome dynamics of CD4
Soon MSF; Lee HJ; Engel JA; Straube J; Thomas BS; Pernold CPS; Clarke LS; Laohamonthonkul P; Haldar RN; Williams CG; Lansink LIM; Moreira ML; Bramhall M; Koufariotis LT; Wood S; Chen X; James KR; Lönnberg T; Lane SW; Belz GT; Engwerda CR; Khoury DS; Davenport MP; Svensson V; Teichmann SA; Haque A
Nat Immunol; 2020 Dec; 21(12):1597-1610. PubMed ID: 33046889
[TBL] [Abstract][Full Text] [Related]
5. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
[TBL] [Abstract][Full Text] [Related]
6. Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
Byrne A; Savas P; Sant S; Li R; Virassamy B; Luen SJ; Beavis PA; Mackay LK; Neeson PJ; Loi S
Nat Rev Clin Oncol; 2020 Jun; 17(6):341-348. PubMed ID: 32112054
[TBL] [Abstract][Full Text] [Related]
7. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Jiang P; Gu S; Pan D; Fu J; Sahu A; Hu X; Li Z; Traugh N; Bu X; Li B; Liu J; Freeman GJ; Brown MA; Wucherpfennig KW; Liu XS
Nat Med; 2018 Oct; 24(10):1550-1558. PubMed ID: 30127393
[TBL] [Abstract][Full Text] [Related]
8. A single amino acid substitution in the active site of Escherichia coli aspartate transcarbamoylase prevents the allosteric transition.
Stieglitz KA; Pastra-Landis SC; Xia J; Tsuruta H; Kantrowitz ER
J Mol Biol; 2005 Jun; 349(2):413-23. PubMed ID: 15890205
[TBL] [Abstract][Full Text] [Related]
9. The 80s loop of the catalytic chain of Escherichia coli aspartate transcarbamoylase is critical for catalysis and homotropic cooperativity.
Macol C; Dutta M; Stec B; Tsuruta H; Kantrowitz ER
Protein Sci; 1999 Jun; 8(6):1305-13. PubMed ID: 10386880
[TBL] [Abstract][Full Text] [Related]
10. Substrate-induced conformational change in a trimeric ornithine transcarbamoylase.
Ha Y; McCann MT; Tuchman M; Allewell NM
Proc Natl Acad Sci U S A; 1997 Sep; 94(18):9550-5. PubMed ID: 9275160
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro studies on the immunosuppressive effects of purine and pyrimidine synthesis inhibitors.
Zeevi A; Yao GZ; Venkataramanan R; Duquesnoy RJ; Todo S; Fung JJ; Starzl TE
Transplant Proc; 1993 Feb; 25(1 Pt 1):781-3. PubMed ID: 7679843
[No Abstract] [Full Text] [Related]
12. Propagation of conformational changes in Ni(II)-substituted aspartate transcarbamoylase: effect of active-site ligands on the regulatory chains.
Johnson RS; Schachman HK
Proc Natl Acad Sci U S A; 1980 Apr; 77(4):1995-9. PubMed ID: 6990418
[TBL] [Abstract][Full Text] [Related]
13. Pyrimidine metabolism in microorganisms.
O'Donovan GA; Neuhard J
Bacteriol Rev; 1970 Sep; 34(3):278-343. PubMed ID: 4919542
[No Abstract] [Full Text] [Related]
14. Kinetics and regulation of the salt-dependent aspartate transcarbamylase of Halobacterium cutirubrum.
Norberg P; Kaplan JG; Kushner DJ
J Bacteriol; 1973 Feb; 113(2):680-6. PubMed ID: 4690963
[TBL] [Abstract][Full Text] [Related]
15. Effect of amino acid substitutions on the catalytic and regulatory properties of aspartate transcarbamoylase.
Robey EA; Wente SR; Markby DW; Flint A; Yang YR; Schachman HK
Proc Natl Acad Sci U S A; 1986 Aug; 83(16):5934-8. PubMed ID: 3526345
[TBL] [Abstract][Full Text] [Related]
16. Active-site-directed inactivation of wheat-germ aspartate transcarbamoylase by pyridoxal 5'-phosphate.
Cole SC; Yon RJ
Biochem J; 1987 Dec; 248(2):403-8. PubMed ID: 3435454
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional structure of carbamoyl phosphate and succinate bound to aspartate carbamoyltransferase.
Gouaux JE; Lipscomb WN
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4205-8. PubMed ID: 3380787
[TBL] [Abstract][Full Text] [Related]
18. Arginine 54 in the active site of Escherichia coli aspartate transcarbamoylase is critical for catalysis: a site-specific mutagenesis, NMR, and X-ray crystallographic study.
Stebbins JW; Robertson DE; Roberts MF; Stevens RC; Lipscomb WN; Kantrowitz ER
Protein Sci; 1992 Nov; 1(11):1435-46. PubMed ID: 1303763
[TBL] [Abstract][Full Text] [Related]
19. Wheat-germ aspartate transcarbamoylase. Steady-state kinetics and stereochemistry of the binding site for L-aspartate.
Grayson JE; Yon RJ; Butterworth PJ
Biochem J; 1979 Nov; 183(2):247-54. PubMed ID: 534495
[TBL] [Abstract][Full Text] [Related]
20. A kinetic model of cooperativity in aspartate transcarbamylase.
Dembo M; Rubinow SI
Biophys J; 1977 Jun; 18(3):245-67. PubMed ID: 329911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
